Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI [Yahoo! Finance]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (OCUL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD